RAPT Therapeutics (NASDAQ:RAPT) Issues Earnings Results

RAPT Therapeutics (NASDAQ:RAPT) posted its earnings results on Thursday. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69), Zacks reports.

RAPT Therapeutics Price Performance

Shares of RAPT stock traded up $0.03 during mid-day trading on Thursday, hitting $1.16. The stock had a trading volume of 130,800 shares, compared to its average volume of 827,314. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $10.05. The firm’s 50-day moving average is $1.27 and its two-hundred day moving average is $1.57. The firm has a market capitalization of $40.38 million, a P/E ratio of -0.42 and a beta of -0.31.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RAPT shares. Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $8.00 to $2.00 in a research note on Monday, November 11th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Wells Fargo & Company dropped their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Thursday, December 26th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.